Why cancer therapies are irrational ?
There is overwhelming knowledge about, how cancer is caused, but all that information does not result in effective prevention and cure. It is clear that cancer is a cellular disease, where homeostatic control of cell division and differentiation is corrupted, resulting in a tumour. The main characteristics of the tumour is:- *Lack of cell division […]
Covid 19 Impact & Challenges as New Normal in Pharma Industry Impact on Business
Impact on Business COVID-19 is first and foremost a humanitarian crisis and the role played ll article by pharmaceutical organizations is fundamentally critical. As pharma leaders focus on their crisis responses, it is important to consider these questions and the implications for their respective companies in increasing their flexibility and better adapting to the post-COVID-19 […]
Future of Clinical Trials in India: Helping our patients more and more.
Today, the pandemic of COVID-19 has created havoc across the world. During the times of this unprecedented crisis, tremendous amount of research is ongoing in the world to finda drug and vaccine against this dreaded disease. Across the globe, people are eagerly looking at the biopharmaceutical industry to come up with a drug and a […]
COVID-19 and the pharmaceutical industry
COVID-19 (Corona Virus Disease) is a good example of how the environment can be VUCA or Volatile, Uncertain, Complex and Ambiguous. In future it will be a business case for management classes and any business forecast or future cast will need to include a section for whether one has proactively prepared for a COVID-19 like […]
Health Meets Hope: The Future of Pharma in India
Covid-19has triggered not only a health crisis but also an economic and social crisis as well. Undoubtedly, it is the science-based pharma industry along with the medical fraternity who are on the front lines of the battle against this global pandemic. And while the industry remains committed to ensuring uninterrupted supplies of medicines to patients, […]
Strategies for Indian Pharmaceutical Companies in the Post-COVID-19 World
Indian Pharmaceutical Market Indian pharmaceutical industry is valued at USD 39 Bn in 2019 and 50% of the market is primarily driven by exports to regulated as well as semi-regulated markets. Currently, India exports drugs to more than 200 countries and vaccines and bio-pharma products to more than 150 countries. Globally, India ranks 3rd in […]
Creating a new collaborative framework to tackle diabetes in India
Over the last few years, we have been repeatedly cautioned about India’s growing diabetes burden and its dubious distinction of being one of the ‘diabetes capitals of the world’. According to the International Diabetes Federation, there are 77 million Indians living with diabetes as of 2019, and that number is set to rise to 101 […]
CRISPR - An Overview
This year marks the tenth anniversary of the seminal paper by Charpentier and Doudna in Science (1) on what can be considered one of the most significant breakthroughs in the field of genetic engineering. In the ensuing years, CRISPR – Clustered Regularly Interspaced Short Palindromic Repeats, has taken the world by storm. In this article, […]
How digitalization is helping the process of doing clinical trials from the Covid days?
On an average it takes more than 12 years to develop new medicines with costs often going up to a few billion dollars. Once medicines are approved by health regulatory authorities and available for use by patients, only a proportion of them comply with their doctor’s prescription in real world scenario. In the development phase […]
Newly adopted methods are influencing the evolution of clinical trials in a post-pandemic world
The COVID 19 pandemic came with tremendous uncertainly but radically changed the world for life sciences companies to do their best to move quickly and safely. The companies undertaking clinical trials had to quickly adjust to support alternative ways to conduct trials also ensuring monitoring and caring for clinical trial participants for which physical access […]
